Innate Pharma SA To Hold Conference Call Transcript
Key Points
- Innate Pharma SA (IPHA) secured a $30 million equity raise, extending its projected cash runway through Q1 2028.
- The strategic partnership with SOBI, including a $75 million upfront payment and up to $40 million in near-term milestones, enables the initiation of the TELAMAC-3 phase 3 study for lacutamab.
- IPH 4502, a second-generation Nectin-4 ADC, has shown preliminary clinical activity in post-PADCEF urothelial cancer, non-small cell lung cancer, and head and neck cancer, with a favorable safety profile.
- The proprietary linker of IPH 4502 has demonstrated stability in patients, supporting the hypothesis of minimized payload release into circulation.
- The upcoming Pacific-9 study readout for monalizumab, with up to $825 million in potential milestones and a 50% profit share in Europe, represents a significant future value opportunity.
- The company is advancing a preclinical ADC portfolio with innovative approaches, including bispecific ADCs and dual-payload ADCs, to address tumor heterogeneity and resistance.
- The $30 million equity raise may dilute existing shareholders, and the company did not provide specific details on the number of patients or follow-up data for IPH 4502 in each indication.
- The TELAMAC-3 study initiation is subject to conditions, including antitrust clearance, which could delay the timeline.
- The company has not yet presented the full data set for IPH 4502, and the next development steps are dependent on the results, which are not yet available.
- The Pacific-9 study primary completion date is not until the end of September, with data expected by year end, leaving uncertainty about the outcome and potential value realization.
- The company's ability to progress its preclinical ADC portfolio is contingent on the success of IPH 4502, and the timeline for communicating on these programs is not until 2027, indicating a long wait for potential catalysts.
- The CEO noted that the company is in a competitive space for Nectin-4 ADCs, and the ambiguity around Lilly's program could pose competitive risks.
Hello, everyone.
Thank you for joining us and welcome to the Innate Pharma webcast call.
(Operator Instructions)
I will now hand the conference over to Stephanie Cornen, Vice President of Investor Relations and Communication at Innate Pharma. Please go ahead.
Good morning and good afternoon, everyone.
Thank you for joining us for the conference call. Before we begin, I would like to remind everyone that today's presentation includes forward-looking statements based on current expectations. These statements involve risk and uncertainty that could cause actual results to differ materially. With that, I will now hand it over to Jonathan.
Thank you, Stephanie, and thank you, everybody, for joining us this morning in the U.S., this afternoon in Europe to discuss this morning's announcement of Innate
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
